ArticleThe Journal of antibiotics2021
Antibiofilm activity of Fmoc-phenylalanine against Gram-positive and Gram-negative bacterial biofilms.
Article in The Journal of antibiotics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 22 citations in OpenAlex.
- Hierarchical Peptide Functionalized Titania Nanotubes: Improving Stability, Promoting Osteogenesis, and Reducing Infection Risk.Small (Weinheim an der Bergstrasse, Germany) · 2026Article
- Biological Evaluation of Some Amino Acids Esters: A Study on Antimicrobial, Antibiofilm, and Molecular Docking.ACS omega · 2026Article
- Z‑Amino Acids Present Innovative Antimicrobial and Antibiofilm Properties against Methicillin-Susceptible and -ResistantACS omega · 2026Article
- Amino acid-based surfactants: sustainable synthesis and antimicrobial mechanisms.Beilstein journal of organic chemistry · 2026Review
- Diastereoselective Synthesis and Biological Evaluation of Spiro[chromane-2,4'-pyrimidin]-2'(3'Molecules (Basel, Switzerland) · 2025Article
- DisarmingPathogens (Basel, Switzerland) · 2025Review
- Anti-Biofilm Agents to OvercomePharmaceuticals (Basel, Switzerland) · 2025Review
- Enhancing Antibacterial Properties of Titanium Implants through Covalent Conjugation of Self-Assembling Fmoc-Phe-Phe Dipeptide on Titania Nanotubes.ACS applied materials & interfaces · 2024Article
- Unraveling the New Perspectives on Antimicrobial Hydrogels: State-of-the-Art and Translational Applications.Gels (Basel, Switzerland) · 2023Review
- Probing the Gelation Synergies and Anti-ACS omega · 2023Article
- Combination drug strategies for biofilm eradication using synthetic and natural agents in KAPE pathogens.Frontiers in cellular and infection microbiology · 2023Review
- Antibacterial and Anti-Inflammatory Properties of Peptide KN-17.Microorganisms · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Biofilm associated infections are the major contributor of mortality, morbidity and financial burden in patients with a bacterial infection. About 65% of all bacterial infections are associated with the information of bacterial biofilms. Bacterial biofilms not only reduce the efficacy of antibacterial treatment but also increases the threat of developing antibacterial resistance. Recently, our group has discovered the antibacterial activity of Fmoc-phenylalanine (Fmoc-F) and other Fmoc-amino acids (Fmoc-AA). Fmoc-F and other Fmoc-AA showed antibacterial activity due to their surfactant properties. Surfactants are known to eradicate biofilm and enhance antimicrobial activity in biofilm. Thus, in the present study, we evaluated the anti-biofilm activity of Fmoc-F against clinically relevant bacteria. We found that Fmoc-F not only inhibits the biofilm formation in Staphylococcus aureus and Pseudomonas aeruginosa, but also eradicates the already formed biofilms over the surface. Further, Fmoc-F coated glass surface resists S. aureus and P. aeruginosa biofilm formation and attachment, when biofilm is grown over the surface. The mechanistic investigation suggests that Fmoc-F reduces the extracellular matrix (ECM) components such as proteins, carbohydrates and eDNA in the biofilm and affect its stability via direct interactions with ECM components and/ or indirectly through reducing bacterial cell population. Finally, we showed that Fmoc-F treatment in combination with vancomycin and ampicillin synergistically inhibit biofilm formation. Overall, the study demonstrates the potential application of Fmoc-F and other Fmoc-AA molecules individually as well as in combination as anti-biofilm coating material for treating biofilm associated infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.